CY1118513T1 - Αναστολεις πρωτεϊνικης κινασης (παραλλαγες), χρηση αυτων στη θεραπεια ογκολογικων νοσων και μια φαρμακευτικη συνθεση βασισμενη σε αυτους - Google Patents

Αναστολεις πρωτεϊνικης κινασης (παραλλαγες), χρηση αυτων στη θεραπεια ογκολογικων νοσων και μια φαρμακευτικη συνθεση βασισμενη σε αυτους

Info

Publication number
CY1118513T1
CY1118513T1 CY20161101178T CY161101178T CY1118513T1 CY 1118513 T1 CY1118513 T1 CY 1118513T1 CY 20161101178 T CY20161101178 T CY 20161101178T CY 161101178 T CY161101178 T CY 161101178T CY 1118513 T1 CY1118513 T1 CY 1118513T1
Authority
CY
Cyprus
Prior art keywords
protein kinase
kinase inhibitors
varieties
composition based
medicinal composition
Prior art date
Application number
CY20161101178T
Other languages
English (en)
Inventor
Germes Grigorievich Chilov
Ilya Yurievich Titov
Original Assignee
Obshchestvo S Ogranichennoy Otvetstvennostyou "Fusion Pharma"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obshchestvo S Ogranichennoy Otvetstvennostyou "Fusion Pharma" filed Critical Obshchestvo S Ogranichennoy Otvetstvennostyou "Fusion Pharma"
Publication of CY1118513T1 publication Critical patent/CY1118513T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με τη θεραπεία ογκολογικών, χρόνιων φλεγμονωδών και παρόμοιων νόσων με τη βοήθεια νέων οικογενειών χημικών ενώσεων που έχουν βελτιωμένη απόδοση αναφορικά με την αναστολή της Ab1 κινάσης και των μεταλλακτών μορφών αυτής, καθώς και άλλων θεραπευτικώς σημαντικών κινασών. Περιγράφει αναστολείς πρωτεϊνικών κινασών στη μορφή ενώσεων του γενικού τύπου (I) και ενώσεων του γενικού τύπου (II), ή ενός ταυτομερούς, ενός μεμονωμένου ισομερούς, ενός μείγματος ισομερών, ενός φαρμακευτικά αποδεκτού άλατος, ενός επιδιαλυτώματος ή ενός υδρίτη αυτών.
CY20161101178T 2011-06-16 2016-11-16 Αναστολεις πρωτεϊνικης κινασης (παραλλαγες), χρηση αυτων στη θεραπεια ογκολογικων νοσων και μια φαρμακευτικη συνθεση βασισμενη σε αυτους CY1118513T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2011124304/04A RU2477723C2 (ru) 2011-06-16 2011-06-16 Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
PCT/RU2012/000423 WO2012173521A2 (ru) 2011-06-16 2012-05-29 Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе

Publications (1)

Publication Number Publication Date
CY1118513T1 true CY1118513T1 (el) 2017-07-12

Family

ID=47357651

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161101178T CY1118513T1 (el) 2011-06-16 2016-11-16 Αναστολεις πρωτεϊνικης κινασης (παραλλαγες), χρηση αυτων στη θεραπεια ογκολογικων νοσων και μια φαρμακευτικη συνθεση βασισμενη σε αυτους

Country Status (22)

Country Link
US (1) US9522910B2 (el)
EP (1) EP2743266B8 (el)
AU (1) AU2012269818B2 (el)
CA (1) CA2850137C (el)
CY (1) CY1118513T1 (el)
DK (1) DK2743266T3 (el)
EA (1) EA026704B1 (el)
ES (1) ES2602797T3 (el)
HK (1) HK1195771A1 (el)
HR (1) HRP20161478T1 (el)
HU (1) HUE031837T2 (el)
IL (1) IL232357A (el)
IN (1) IN2014MN00635A (el)
LT (1) LT2743266T (el)
PL (1) PL2743266T3 (el)
PT (1) PT2743266T (el)
RS (1) RS55380B1 (el)
RU (1) RU2477723C2 (el)
SI (1) SI2743266T1 (el)
SM (1) SMT201600398B (el)
UA (1) UA115228C2 (el)
WO (1) WO2012173521A2 (el)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2918588B1 (en) 2010-05-20 2017-05-03 Array Biopharma, Inc. Macrocyclic compounds as TRK kinase inhibitors
WO2013170770A1 (zh) * 2012-05-16 2013-11-21 上海医药集团股份有限公司 具有抗肿瘤活性的乙炔衍生物
US8859553B2 (en) * 2012-07-30 2014-10-14 Astar Biotech Llc Protein kinase inhibitors
CN103664787B (zh) * 2012-09-17 2015-09-09 南京圣和药业股份有限公司 炔杂芳环化合物及其应用
CN104341416B (zh) * 2013-07-31 2017-03-29 南京圣和药业股份有限公司 蛋白酪氨酸激酶抑制剂及其应用
US10172839B2 (en) 2014-03-06 2019-01-08 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
EP3113776B1 (en) * 2014-03-06 2021-01-13 University of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
AR104259A1 (es) * 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
CN106146391A (zh) 2015-04-15 2016-11-23 中国科学院上海药物研究所 5-芳香炔基取代的苯甲酰胺类化合物及其制备方法、药物组合物和用途
PT3322706T (pt) 2015-07-16 2021-03-08 Array Biopharma Inc Compostos de pirazolo[1,5-a]piridina substituídos como inibidores da quinase do ret
RU2652992C2 (ru) * 2016-04-18 2018-05-04 Общество С Ограниченной Ответственностью "Фьюжн Фарма" Новая кристаллическая солевая форма 3-(1,2,4-триазоло[4,3-а]пиридин-3-илэтинил)-4-метил-n-(4-((4-метилпиперазин-1-ил)метил)-3-трифторметилфенил)бензамида для медицинского применения
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
RU2664420C1 (ru) * 2017-10-31 2018-08-17 Общество С Ограниченной Ответственностью "Фьюжн Фарма" ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ДОЗИРОВКА И СПОСОБ ЛЕЧЕНИЯ Ph+ ЛЕЙКЕМИЙ
JP7060694B2 (ja) 2018-01-18 2022-04-26 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物
JP7061195B2 (ja) 2018-01-18 2022-04-27 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［３，４－ｄ］ピリミジン化合物
CN111615514B (zh) 2018-01-18 2022-10-11 奥瑞生物药品公司 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物
CA3117927A1 (en) * 2018-11-02 2020-05-07 Merck Sharp & Dohme Corp. 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
WO2022015051A1 (ko) * 2020-07-14 2022-01-20 주식회사 보로노이바이오 아릴 또는 헤테로아릴 유도체, 및 이를 유효성분으로 포함하는 키나아제 관련 질환 예방 또는 치료용 약학적 조성물
GB202209210D0 (en) * 2022-06-23 2022-08-10 Univ Strathclyde Cycloaddition reactions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60120193T2 (de) 2000-09-15 2007-03-29 Vertex Pharmaceuticals Inc., Cambridge Pyrazolverbindungen als protein-kinasehemmer
RU2340611C2 (ru) * 2000-09-15 2008-12-10 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, используемые в качестве ингибиторов протеинкиназы
US7709520B2 (en) 2000-10-06 2010-05-04 The Texas A&M University System Diindolylmethane and C-substituted diindolylmethane compositions and methods for the treatment of multiple cancers
AU2005206571B8 (en) 2004-01-23 2010-09-02 Amgen Inc. Compounds and methods of use
US7745437B2 (en) 2004-06-10 2010-06-29 Irm Llc Compounds and compositions as protein kinase inhibitors
US8158825B2 (en) 2005-06-24 2012-04-17 Merck Sharp & Dohme Corp. Modified malonate derivatives
WO2007075869A2 (en) * 2005-12-23 2007-07-05 Ariad Pharmaceuticals, Inc. Bicyclic heteroaryl compounds
JP2009526855A (ja) 2006-02-16 2009-07-23 ミレニアム・ファーマシューティカルズ・インコーポレイテッド アルファカルボリンおよびその使用
EP2023933A4 (en) * 2006-05-08 2011-02-23 Ariad Pharma Inc HETEROARYL ACETYLENE COMPOUNDS
JP2009539403A (ja) 2006-06-13 2009-11-19 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌を診断および処置するための組成物および方法
US7612085B2 (en) 2006-07-11 2009-11-03 Washington University Sigma 2 receptor ligands and therapeutic uses therefor
CA2673368C (en) 2006-12-19 2014-10-28 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
EP2167058B1 (en) 2007-06-18 2015-08-12 University Of Louisville Research Foundation, Inc. Family of pfkfb3 inhibitors with anti-neoplastic activities
JP5314050B2 (ja) 2008-01-23 2013-10-16 ブリストル−マイヤーズ スクイブ カンパニー ４−ピリジノン化合物および癌についてのその使用
US8211911B2 (en) 2008-08-19 2012-07-03 Guoqing Paul Chen Compounds as kinase inhibitors
US8188109B2 (en) 2009-07-20 2012-05-29 Naxospharma S.R.L. Benzoquinolizinium salt derivatives as anticancer agents
US8242282B2 (en) 2010-05-18 2012-08-14 Taipei Medical University Histone deacetylase inhibitors
RU2011113236A (ru) 2011-04-07 2012-10-20 Общество с ограниченной ответственностью "Фьюжн Фарма" (RU) Новые химические соединения для лечения онкологических заболеваний
WO2013170770A1 (zh) * 2012-05-16 2013-11-21 上海医药集团股份有限公司 具有抗肿瘤活性的乙炔衍生物
US8859553B2 (en) 2012-07-30 2014-10-14 Astar Biotech Llc Protein kinase inhibitors

Also Published As

Publication number Publication date
CA2850137C (en) 2016-10-25
LT2743266T (lt) 2016-12-12
IL232357A0 (en) 2014-07-01
IN2014MN00635A (el) 2015-07-03
CA2850137A1 (en) 2012-12-20
HUE031837T2 (en) 2017-08-28
IL232357A (en) 2017-05-29
EA201491356A1 (ru) 2015-01-30
PT2743266T (pt) 2016-10-14
SMT201600398B (it) 2017-01-10
EP2743266B1 (en) 2016-08-17
WO2012173521A3 (ru) 2013-03-28
WO2012173521A2 (ru) 2012-12-20
EP2743266B8 (en) 2016-09-28
RU2011124304A (ru) 2012-12-27
EP2743266A4 (en) 2015-03-11
HK1195771A1 (zh) 2014-11-21
PL2743266T3 (pl) 2017-02-28
HRP20161478T1 (hr) 2016-12-16
SI2743266T1 (en) 2017-02-28
ES2602797T3 (es) 2017-02-22
EP2743266A2 (en) 2014-06-18
RS55380B1 (sr) 2017-03-31
US20140213592A1 (en) 2014-07-31
DK2743266T3 (en) 2016-12-05
UA115228C2 (uk) 2017-10-10
AU2012269818B2 (en) 2016-05-19
RU2477723C2 (ru) 2013-03-20
EA026704B1 (ru) 2017-05-31
AU2012269818A1 (en) 2014-06-26
US9522910B2 (en) 2016-12-20

Similar Documents

Publication Publication Date Title
CY1118513T1 (el) Αναστολεις πρωτεϊνικης κινασης (παραλλαγες), χρηση αυτων στη θεραπεια ογκολογικων νοσων και μια φαρμακευτικη συνθεση βασισμενη σε αυτους
CY1125436T1 (el) Αναστολεις dna-pk
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
CY1120866T1 (el) Παρεμποδιστες dna-pk
CY1119227T1 (el) Παραγωγα πυριδινης ως ηπιοι αναστολεις της rock
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
CY1118012T1 (el) Συνθεσεις αναστολεων κινασης και η χρηση αυτων για την αγωγη καρκινου και αλλων νοσηματων σχετικων προς τις κινασες
EA201490949A1 (ru) Ингибиторы киназ
EA201792116A1 (ru) Ингибитор янус-киназы
TN2011000293A1 (en) Protein kinase inhibitors
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
MX2015012822A (es) 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante.
SG10201810154WA (en) Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
EA201791576A1 (ru) Ингибитор jak
MX346186B (es) Inhibidores de proteina cinasas.
PE20151501A1 (es) Inhibidores de prmt5 y sus usos
CL2013002690A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer.
MX355945B (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
EA201270730A1 (ru) ИНГИБИТОРЫ КИНАЗЫ Cdc7 И ИХ ПРИМЕНЕНИЕ
EA202090413A1 (ru) Пиразоло- и триазолобициклические соединения в качестве ингибиторов jak киназы
EA201490161A1 (ru) Соединения - ингибиторы сигналинга, опосредуемого рецептором notch
MA32183B1 (fr) Pyrimidylcyclopentanes hydroxylés utilisés comme inhibiteurs de protéine kinase akt
ATE540038T1 (de) Heterocyclen als proteinkinaseinhibitoren
WO2012119006A3 (en) Derivatives of pyrazole-substituted amino-heteroaryl compounds
PL404138A1 (pl) Pochodne kwasu benzoesowego jako inhibitory receptora IL-15Rα